RxDoctor Payments Data

Matthew Jackson, MD

Family Medicine · Newport, ARNPI 1083689855

Payments from drug & device makers

$559in general payments, 2019–2025

Across 34 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$172
  • Novo Nordisk$104
  • GSK$88
  • Abbott$76
  • AbbVie$30
  • Xeris Pharmaceuticals, Inc.$20
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$54497%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$559 in reported general payments places this provider in the 45th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$335,306
Medicare patients
350
Services billed
12,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$135,805
EliquisApixaban214$133,571
JardianceEmpagliflozin106$92,870
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$66,042
TrulicityDulaglutide48$54,276
MounjaroTirzepatide36$37,310
FarxigaDapagliflozin Propanediol41$36,288
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr64$33,254
JanuviaSitagliptin Phosphate36$29,971
XareltoRivaroxaban44$29,963
LinzessLinaclotide32$23,130
EntrestoSacubitril/Valsartan24$18,679
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$18,595
MyrbetriqMirabegron26$17,990
MovantikNaloxegol Oxalate27$17,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$17$140,695229 claims
Novo NordiskOzempic$104$135,805138 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$88$109,328183 claims
Boehringer IngelheimJardiance$15$92,870106 claims
AbbVieLinzess, Ubrelvy$30$34,78844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Newport

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →